Minnesota Glomerular Disease Program
Mission
Provide expert, individualized care to patients with any glomerular disease, with ongoing Phase 2 and Phase 3 clinical trials in Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy. For more information, email [email protected]
Covered Diseases
- Focal Segmental Glomerulosclerosis (FSGS)
- Membranous nephropathy
- Minimal change disease
- IgA nephropathy
- Immune complex mediated diseases
- C3 Glomerulopathy
- Fibrillary Glomerular Disease
- Cryoglobulinemia
- Anti-Glomerular Basement Membrane (anti-GBM) Disease
- Alport Syndrome
- Thin basement membrane disease
- Vasculitis
- Lupus Nephritis
- For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage
Goals
- Provide expert care for patients with glomerular disease.
- Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
- Provide patients with access to cutting-edge clinical trials.
- Facilitate translational research.
- Provide a venue for health care providers training in the care of patients with glomerular disease.
Highlights
- September 2023: Enrolled the 60th patient into the registry.
Our Team
Physicians
- Shanthi Balani, MD
- Milind Junghare, MD
- Patrick H. Nachman, MD
- Michelle Rheault, MD (Pediatrics)
- Surabhi Thakar, MD
- Katti Woerner, MD
Research Team
- Amy Hanson, CCRC, Clinical Research Coordinator, Pediatrics
- Anael Kuperwajs Cohen, CCRC, Clinical Research Coordinator, Pediatrics
- Scott Rajala, CCRP, Clinical Research Coordinator
Ongoing Clinical Trials
Anti-GBM
A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Andrew Johnson, MD
Nattawat Klomjit, MD
Sahar Koubar, MBBS
Aahd Kubbara, MD
Katie Pendleton, MD
Sami Safadi, MD
Study Coordinator
Nicolas Rauwolf | [email protected]
Focal Segmental Glomerulosclerosis (FSGS)
The Nephrotic Syndrome Study Network (NEPTUNE)
Principal Investigator:
Patrick Nachman, MD
Co-Principal Investigators:
Michelle Rheault, MD
Angie Lobo, MD
Study Coordinators:
Scott Rajala, CCRP | [email protected]
Nicolas Rauwolf | [email protected]
IgA Nephropathy
New Study Starting Soon!
Membranoproliferative Glomerulonephritis
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN)
Principal Investigator
Nattawat Klomjit, MD
Co-Investigators
Patrick H. Nachman, MD
Study Coordinator:
Nicolas Rauwolf | [email protected]
Membranous Nephropathy
Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)
Principal Investigator
Patrick Nachman, MD
Co-Investigator
Surabhi Thakar, MD
Katti Woerner, MD
Study Coordinators
Nicolas Rauwolf | [email protected]
The Nephrotic Syndrome Study Network (NEPTUNE)
Principal Investigator:
Patrick Nachman, MD
Co-Principal Investigators:
Michelle Rheault, MD
Angie Lobo, MD
Study Coordinators:
Scott Rajala, CCRP | [email protected]
Nicolas Rauwolf | [email protected]